{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:04:57Z","timestamp":1790597097129,"version":"4.1.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Discontinuation of incretin-based pharmacotherapy is frequent and is associated with weight regain and metabolic relapse, including deterioration in cardiometabolic risk factors. New strategies are needed to preserve metabolic stability and body weight after treatment withdrawal. Whether continuous glucose monitoring (CGM) can facilitate early detection of metabolic relapse or support long-term weight maintenance after discontinuation remains unknown. This narrative review examines the indirect evidence supporting CGM use after discontinuation of incretin-based obesity pharmacotherapy, focusing primarily on adults with obesity without established diabetes, including those with normoglycemia or prediabetes. CGM can characterize postprandial glucose responses and glycemic variability under free-living conditions while also offering real-time behavioral feedback. However, no prospective studies have established whether CGM-derived metrics precede or predict weight regain, nor whether CGM-guided interventions improve long-term weight-maintenance outcomes in this setting. Moreover, validated CGM thresholds for identifying metabolic relapse in individuals without diabetes have yet to be defined. We outline a hypothesis-generating three-phase monitoring framework for the prospective evaluation of CGM alongside body weight, appetite, dietary intake, and physical activity during the post-discontinuation transition period. If validated, unfavorable CGM trends could support earlier individualized behavioral or pharmacological intervention, before clinically meaningful weight regain or metabolic relapse occurs. Potential benefits must be balanced against costs, skin reactions, anxiety, and unnecessary dietary restrictions arising from overinterpreting unvalidated signals. CGM-guided post-pharmacotherapy care, therefore, remains investigational and requires prospective validation.<\/jats:p>","DOI":"10.3389\/fendo.2026.1892632","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:52:16Z","timestamp":1790596336000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Continuous glucose monitoring after discontinuation of incretin-based obesity pharmacotherapy: indirect evidence and a research framework for metabolic stability and weight maintenance"],"prefix":"10.3389","volume":"17","author":[{"given":"Andrijana","family":"Koceva","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetology, University Medical Center Maribor","place":["Maribor, Slovenia"]},{"name":"Faculty of Medicine, University of Maribor","place":["Maribor, Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Janez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana","place":["Ljubljana, Slovenia"]},{"name":"Faculty of Medicine, University of Ljubljana","place":["Ljubljana, Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Jensterle","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana","place":["Ljubljana, Slovenia"]},{"name":"Faculty of Medicine, University of Ljubljana","place":["Ljubljana, Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70062-7","article-title":"Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications","volume":"1","author":"Stefan","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60812-X","article-title":"Quantification of the effect of energy imbalance on bodyweight","volume":"378","author":"Hall","year":"2011","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112434","article-title":"Optimising obesity management: integrating continuous glucose monitoring with GLP-1 receptor agonists","volume":"228","author":"Gupta","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-0906","article-title":"Using continuous glucose monitoring to motivate physical activity in overweight and obese adults: A pilot study","volume":"29","author":"Liao","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1001\/jamainternmed.2025.6112","article-title":"Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: A post hoc analysis of the SURMOUNT-4 trial","volume":"186","author":"Horn","year":"2026","journal-title":"JAMA Intern Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103680","article-title":"Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis","volume":"90","author":"Tzang","year":"2025","journal-title":"eClinicalMedicine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70713","article-title":"Clinical management of weight regain and cardiometabolic consequences after discontinuation of GLP\u20101 receptor agonists","volume":"28","author":"Shah","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-3092","article-title":"Dose-dependent associations of dietary glycemic index, glycemic load, and fiber with 3-year weight loss maintenance and glycemic status in a high-risk population: A secondary analysis of the Diabetes Prevention Study PREVIEW","volume":"44","author":"Zhu","year":"2021","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.05.749","article-title":"Moving beyond glycated hemoglobin to glucose patterns: Newer indications for continuous glucose monitor use","volume":"31","author":"Agarwal","year":"2025","journal-title":"Endocrine Pract"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-024-01311-6","article-title":"Prediction of metabolic subphenotypes of type 2 diabetes via continuous glucose monitoring and machine learning","volume":"9","author":"Metwally","year":"2024","journal-title":"Nat BioMed Eng"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112111","article-title":"The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes","volume":"223","author":"Battelino","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02908-9","article-title":"Continuous glucose monitoring and intrapersonal variability in fasting glucose","volume":"30","author":"Shilo","year":"2024","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cmet.2023.04.002","article-title":"CGMap: Characterizing continuous glucose monitor data in thousands of non-diabetic individuals","volume":"35","author":"Keshet","year":"2023","journal-title":"Cell Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae626","article-title":"Defining continuous glucose monitor time in range in a large, community-based cohort without diabetes","volume":"110","author":"Spartano","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.05.742","article-title":"Continuous glucose monitoring for prediabetes: Roles, evidence, and gaps","volume":"31","author":"Zahalka","year":"2025","journal-title":"Endocrine Pract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.11.001","article-title":"Personalized nutrition by prediction of glycemic responses","volume":"163","author":"Zeevi","year":"2015","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/1932296814537039","article-title":"Glycemic variability in nondiabetic morbidly obese persons: Results of an observational study and review of the literature","volume":"8","author":"Salkind","year":"2014","journal-title":"J Diabetes Sci Technol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/nu13093092","article-title":"Impact of lifestyle behaviors on postprandial hyperglycemia during continuous glucose monitoring in adult males with overweight\/obesity but without diabetes","volume":"13","author":"Kishimoto","year":"2021","journal-title":"Nutrients"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-1395","article-title":"Association of insulin resistance and insulin secretion indices and glucose metrics from continuous glucose monitoring in people with obesity","volume":"49","author":"Belfort-DeAguiar","year":"2026","journal-title":"Diabetes Care"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-2154","article-title":"Investigating the spectrum of normoglycemia: Time in glycemic ranges and their association with metabolic outcomes in individuals without diabetes","volume":"49","author":"Godneva","year":"2026","journal-title":"Diabetes Care"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2024.02.014","article-title":"Glycemic variability assessed using continuous glucose monitoring in individuals without diabetes and associations with cardiometabolic risk markers: A systematic review and meta-analysis","volume":"43","author":"Hjort","year":"2024","journal-title":"Clin Nutr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S2213-8587(25)00333-X","article-title":"Staging prediabetes and type 2 diabetes: the time to start is now","volume":"14","author":"Shah","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/19322968241242487","article-title":"Continuous glucose monitoring for prediabetes: What are the best metrics","volume":"18","author":"Zahalka","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"19322968261426384","DOI":"10.1177\/19322968261426384","article-title":"Differences in continuous glucose monitoring metrics between prediabetes and normoglycemia: A systematic review and meta-analysis","author":"R\u00e1k\u00f3czi","year":"2026","journal-title":"J Diabetes Sci Technol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/nu16234005","article-title":"Enhancing the impact of individualized nutrition therapy with real-time continuous glucose monitoring feedback in overweight and obese individuals with prediabetes","volume":"16","author":"Basiri","year":"2024","journal-title":"Nutrients"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/nu17091507","article-title":"Effects of individualized nutrition therapy and continuous glucose monitoring on dietary and sleep quality in individuals with prediabetes and overweight or obesity","volume":"17","author":"Basiri","year":"2025","journal-title":"Nutrients"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2196\/44359","article-title":"Use of biological feedback as a health behavior change technique in adults: Scoping review","volume":"25","author":"Richardson","year":"2023","journal-title":"J Med Internet Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2023.1151918","article-title":"Understanding health behavior change by motivation and reward mechanisms: a review of the literature","volume":"17","author":"Michaelsen","year":"2023","journal-title":"Front Behav Neurosci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2836","article-title":"Continuous glucose monitoring in the self-management of type 2 diabetes: A paradigm shift","volume":"39","author":"Cox","year":"2016","journal-title":"Diabetes Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjnut.2023.03.007","article-title":"The relationship between dietary patterns and glycemic variability in people with impaired glucose tolerance","volume":"153","author":"Dimova","year":"2023","journal-title":"J Nutr"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1038\/s41467-026-70308-3","article-title":"Associations of continuous glucose monitor derived time in range and glycaemic variability with diet lifestyle and demographics","volume":"17","author":"Bermingham","year":"2026","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad639","article-title":"Lifestyle intervention with smartphone app and isCGM for people at high risk of type 2 diabetes: Randomized trial","volume":"109","author":"Kitazawa","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114521002944","article-title":"Eating architecture in adults at increased risk of type 2 diabetes: associations with body fat and glycaemic control","volume":"128","author":"Zhao","year":"2022","journal-title":"Br J Nutr"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.01.006","article-title":"Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial","volume":"80","author":"Allen","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.06.015","article-title":"Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes","volume":"82","author":"Yoo","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"B42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12966-024-01692-6","article-title":"The efficacy of using continuous glucose monitoring as a behaviour change tool in populations with and without diabetes: a systematic review and meta-analysis of randomised controlled trials","volume":"21","author":"Richardson","year":"2024","journal-title":"Int J Behav Nutr Phys Act"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2025.10.003","article-title":"Understanding the benefits and psychological burdens of using continuous glucose monitoring for lifestyle change: A mixed-methods cross-sectional study","volume":"19","author":"Richardson","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1139\/apnm-2013-0512","article-title":"Effects of high-intensity interval exercise versus continuous moderate-intensity exercise on postprandial glycemic control assessed by continuous glucose monitoring in obese adults","volume":"39","author":"Little","year":"2014","journal-title":"Appl Physiol Nutr Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3945\/jn.115.210617","article-title":"Six and 12 weeks of caloric restriction increases \u03b2 cell function and lowers fasting and postprandial glucose concentrations in people with type 2 diabetes1\u20133","volume":"145","author":"Sathananthan","year":"2015","journal-title":"J Nutr"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.729","article-title":"Continuous glucose monitoring captures glycemic variability in obesity after sleeve gastrectomy: A prospective cohort study","volume":"10","author":"Dorcely","year":"2024","journal-title":"Obes Sci Pract"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2026.106738","article-title":"Optimizing weight loss maintenance: Can continuous glucose monitoring play a role (OWL-CGM)? A randomized controlled feasibility trial","volume":"64","author":"Hatta","year":"2026","journal-title":"Clin Nutr"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103796","article-title":"Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression","volume":"93","author":"Budini","year":"2026","journal-title":"eClinicalMedicine"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/lifemeta\/loaf024","article-title":"Weight loss maintenance after tirzepatide cessation in people with overweight\/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial","author":"Chen","year":"2025","journal-title":"Life Metab"},{"key":"B51","doi-asserted-by":"publisher","first-page":"102038","DOI":"10.1016\/j.beem.2025.102038","article-title":"Preconception use of GLP-1 and GLP-1\/GIP receptor agonists for obesity treatment","author":"Koceva","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S2213-8587(16)30107-3","article-title":"Influence of maternal obesity on the long-term health of offspring","volume":"5","author":"Godfrey","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf288","article-title":"Preexisting diabetes and pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline","volume":"110","author":"Wyckoff","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30217-0","article-title":"Preconceptional and maternal obesity: epidemiology and health consequences","volume":"4","author":"Poston","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00827-4","article-title":"Pathophysiology from preconception, during pregnancy, and beyond","volume":"404","author":"Hivert","year":"2024","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0528-2","article-title":"Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment","volume":"56","author":"Marbury","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106895","article-title":"Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys","volume":"202","author":"Martin","year":"2024","journal-title":"Eur J Pharm Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.20951","article-title":"Gestational weight gain and pregnancy outcomes after GLP-1 receptor agonist discontinuation","author":"Maya","year":"2025","journal-title":"JAMA"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70615","article-title":"Interpreting pregnancy risk after GLP\u20101 receptor agonists discontinuation","volume":"28","author":"Scairati","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-2149","article-title":"Continuous glucose monitoring profiles in pregnancies with and without gestational diabetes mellitus","volume":"47","author":"Durnwald","year":"2024","journal-title":"Diabetes Care"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.24253","article-title":"Addition of continuous glucose monitoring to glucagon-like peptide 1 receptor agonist treatment for type 2 diabetes mellitus - An economic evaluation","volume":"31","author":"Wright","year":"2025","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1892632\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:52:17Z","timestamp":1790596337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1892632\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":61,"alternative-id":["10.3389\/fendo.2026.1892632"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1892632","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1892632"}}